NAVIGATING ADVANCED NSCLC: A JOURNEY THROUGH DAILY CLINICAL MANAGEMENT
Webcast based on a satellite symposium at ESMO 2017

FACULTY

Maurice Pérol

Maurice Pérol
Léon Bérard Cancer Centre, Lyon, France

Maurice Pérol, MD, is the Head of Thoracic Oncology in the Medical Oncology Department of Léon Bérard Cancer Center, Lyon, France. He was Associate Professor of Pneumology and Head of the Department of Thoracic Oncology at the Croix-Rousse University Hospital in Lyon, France from 1993 until 2011.

Dr Pérol field of scientific work includes clinical phase 1, 2, and 3 studies in lung cancer, especially in advanced non-small-cell lung cancer (NSCLC); he has been a principal investigator or key investigator in several French and international cooperative studies. Of note, he was the principal investigator of the IFCT-GFPC 0502 and 1101 maintenance French studies, which involved more than 70 centres in France, and was the co-principal investigator of the international REVEL phase III study assessing ramucirumab in second-line treatment of NSCLC.

He is an active member of many scientific societies, including the American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer (IASLC), the European Society for Medical Oncology (ESMO), and collaborative groups. He was past Chair of the Groupe Français de Pneumo-Cancérologie (GFPC) and Executive Board member of the French Cooperative Group of Thoracic Oncology, Intergroupe Francophone de Cancérologie Thoracique (IFCT). He is member of the IFCT Scientific Board and the Scientific Committee of European Thoracic Oncology Platform (ETOP). He is the author or co-author of more than 160 publications in peer-reviewed journals.


Joachim G. Aerts

Joachim G. Aerts
Thoracic Oncology Department, Erasmus MC, Rotterdam, and Department of Pulmonology, Amphia Hospital, Breda, Netherlands

Joachim Aerts, MD, PhD, is currently Chair of the Thoracic Oncology Department at the Erasmus University Medical Center (Erasmus MC) in Rotterdam, the Netherlands, and pulmonary physician at Amphia Hospital in Breda, the Netherlands. He obtained his medical degree and completed his PhD studies both in 1996 at the Erasmus University.

His research interests include preventive medicine, pathophysiology, and different treatment options in thoracic oncology. He conducts basic, translational, and clinical studies mainly in lung cancer and mesothelioma, with a special focus on onco-immunology. His group has developed a new concept of immunotherapy in mesothelioma for which he was granted a HORIZON subsidy from the European Union. Professor Aerts is Principal Investigator for several national and international studies.

Professor Aerts is a member of several major scientific societies, including the International Association for the Study of Lung Cancer (IASLC), the American Association for Cancer Research (AACR), the American Society of Clinical Oncology (ASCO), and the European Society for Medical Oncology (ESMO). He has authored or co-authored over 120 publications in peer-reviewed journals and books.


Robert Pirker

Robert Pirker
Medical University of Vienna, Austria

Robert Pirker is currently Professor of Medicine and Program Director for Lung Cancer at the Department of Medicine I, Medical University of Vienna, Austria. He obtained a master’s degree in Biochemistry in 1978 and a medical degree in 1979, from the University of Vienna, following which he trained in internal medicine, hemato-oncology and nuclear medicine at the University of Vienna. He was NIH Visiting Fellow at the Laboratory of Molecular Biology, National Cancer Institute, Bethesda, MD, USA, from 1983 to 1986.

Professor Pirker’s research interests include: chemotherapy and targeted therapy of lung cancer; drug-resistance mechanisms in cancer; predictive biomarkers; and management of chemotherapy-induced anaemia. He has been involved in the characterization of predictive factors with regard to adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer (NSCLC). He has published more than 190 articles, reviews or book chapters.

Professor Pirker is a current member of the International Association for the Study of Lung Cancer (IASLC) and Chair of the IASLC Education Committee, and he has served as a European Society for Medical Oncology (ESMO) faculty member on chest tumours. He was Congress President of the 8th and 14th Central European Lung Cancer congresses; Chair of the Scientific Committee of the European Multidisciplinary Conference on Thoracic Oncology in 2009; and Conference President of the IASLC 17th World Conference on Lung Cancer in 2016.


Pieter Postmus

Pieter Postmus
University of Liverpool, UK

Pieter Postmus, MD, graduated from with an MD from the University of Groningen, the Netherlands, in 1976. He trained as a pulmonologist in the University Hospital of Groningen from 1977 to 1981, and has worked in the field of thoracic oncology since 1978. He defended his doctoral thesis "New approaches in small-cell-lung cancer" in 1985, and became Associate Professor in the Department of Pulmonary Diseases at the University Hospital of Groningen in 1989. He was appointed Head of Department and Professor of Pulmonary Diseases at the VU University Medical Center in Amsterdam in 1992, and took up his current position as Professor of Thoracic Oncology at the University of Liverpool, UK, in 2015.

Professor Postmus research in thoracic oncology focuses on early detection, endobronchial therapy, staging procedures, testing and introducing new drugs, and new combinations drug combinations. He is also keenly interested in communication with patients and their relatives, and in how to optimally inform them on their disease and treatment.

Professor Postmus has published widely in peer-reviewed journals. He was a board member of International Association for the Study of Lung Cancer (IASLC) from 2003 to 2011, and was President of the World Conference on Lung Cancer in 2011.

This educational activity is provided by Excerpta Medica. Independent sponsorship for this educational activity was provided by Lilly Oncology.